OBJECTIVE: Calcific aortic valve disease (CAVD) is a major cause of aortic stenosis (AS) and cardiac insufficiency. Patients with type II diabetes mellitus (T2DM) are at heightened risk for CAVD, and their valves have greater calcification than nondiabetic valves. No drugs to prevent or treat CAVD exist, and animal models that might help identify therapeutic targets are sorely lacking. To develop an animal model mimicking the structural and functional features of CAVD in people with T2DM, we tested a diabetogenic, procalcific diet and its effect on the incidence and severity of CAVD and AS in the, LDLr-/-ApoB100/100 mouse model. RESULTS: LDLr-/-ApoB100/100 mice fed a customized diabetogenic, procalcific diet (DB diet) developed hyperglycemia, hyperlipidemia, increased atherosclerosis, and obesity when compared with normal chow fed LDLr-/-ApoB100/100 mice, indicating the development of T2DM and metabolic syndrome. Transthoracic echocardiography revealed that LDLr-/-ApoB100/100 mice fed the DB diet had 77% incidence of hemodynamically significant AS, and developed thickened aortic valve leaflets and calcification in both valve leaflets and hinge regions. In comparison, normal chow (NC) fed LDLr-/-ApoB100/100 mice had 38% incidence of AS, thinner valve leaflets and very little valve and hinge calcification. Further, the DB diet fed mice with AS showed significantly impaired cardiac function as determined by reduced ejection fraction and fractional shortening. In vitro mineralization experiments demonstrated that elevated glucose in culture medium enhanced valve interstitial cell (VIC) matrix calcium deposition. CONCLUSIONS: By manipulating the diet we developed a new model of CAVD in T2DM, hyperlipidemic LDLr-/-ApoB100/100 that shows several important functional, and structural features similar to CAVD found in people with T2DM and atherosclerosis including AS, cardiac dysfunction, and inflamed and calcified thickened valve cusps. Importantly, the high AS incidence of this diabetic model may be useful for mechanistic and translational studies aimed at development of novel treatments for CAVD.
OBJECTIVE:Calcific aortic valve disease (CAVD) is a major cause of aortic stenosis (AS) and cardiac insufficiency. Patients with type II diabetes mellitus (T2DM) are at heightened risk for CAVD, and their valves have greater calcification than nondiabetic valves. No drugs to prevent or treat CAVD exist, and animal models that might help identify therapeutic targets are sorely lacking. To develop an animal model mimicking the structural and functional features of CAVD in people with T2DM, we tested a diabetogenic, procalcific diet and its effect on the incidence and severity of CAVD and AS in the, LDLr-/-ApoB100/100 mouse model. RESULTS:LDLr-/-ApoB100/100 mice fed a customized diabetogenic, procalcific diet (DB diet) developed hyperglycemia, hyperlipidemia, increased atherosclerosis, and obesity when compared with normal chow fed LDLr-/-ApoB100/100 mice, indicating the development of T2DM and metabolic syndrome. Transthoracic echocardiography revealed that LDLr-/-ApoB100/100 mice fed the DB diet had 77% incidence of hemodynamically significant AS, and developed thickened aortic valve leaflets and calcification in both valve leaflets and hinge regions. In comparison, normal chow (NC) fed LDLr-/-ApoB100/100 mice had 38% incidence of AS, thinner valve leaflets and very little valve and hinge calcification. Further, the DB diet fed mice with AS showed significantly impaired cardiac function as determined by reduced ejection fraction and fractional shortening. In vitro mineralization experiments demonstrated that elevated glucose in culture medium enhanced valve interstitial cell (VIC) matrix calcium deposition. CONCLUSIONS: By manipulating the diet we developed a new model of CAVD in T2DM, hyperlipidemic LDLr-/-ApoB100/100 that shows several important functional, and structural features similar to CAVD found in people with T2DM and atherosclerosis including AS, cardiac dysfunction, and inflamed and calcified thickened valve cusps. Importantly, the high AS incidence of this diabetic model may be useful for mechanistic and translational studies aimed at development of novel treatments for CAVD.
Authors: Martin Briand; Isabelle Lemieux; Jean G Dumesnil; Patrick Mathieu; Amélie Cartier; Jean-Pierre Després; Marie Arsenault; Jacques Couet; Philippe Pibarot Journal: J Am Coll Cardiol Date: 2006-05-15 Impact factor: 24.094
Authors: Corey H Mjaatvedt; Christine B Kern; Russel A Norris; Sarah Fairey; Courtney L Cave Journal: Anat Rec A Discov Mol Cell Evol Biol Date: 2005-08
Authors: Veena Naik; Elizabeth M Leaf; Jie Hong Hu; Hsueh-Ying Yang; Ngoc B Nguyen; Cecilia M Giachelli; Mei Y Speer Journal: Cardiovasc Res Date: 2012-03-21 Impact factor: 10.787
Authors: Kazuyuki Yahagi; Frank D Kolodgie; Christoph Lutter; Hiroyoshi Mori; Maria E Romero; Aloke V Finn; Renu Virmani Journal: Arterioscler Thromb Vasc Biol Date: 2016-12-01 Impact factor: 8.311
Authors: Helmut Baumgartner; Judy Hung; Javier Bermejo; John B Chambers; Thor Edvardsen; Steven Goldstein; Patrizio Lancellotti; Melissa LeFevre; Fletcher Miller; Catherine M Otto Journal: J Am Soc Echocardiogr Date: 2017-04 Impact factor: 5.251
Authors: Jesper Hjortnaes; Jonathan Butcher; Jose-Luiz Figueiredo; Mark Riccio; Rainer H Kohler; Kenneth M Kozloff; Ralph Weissleder; Elena Aikawa Journal: Eur Heart J Date: 2010-07-02 Impact factor: 29.983
Authors: Anne B Rossebø; Terje R Pedersen; Christopher Allen; Kurt Boman; John Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; V Antero Y Kesäniemi; William Malbecq; Christoph Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer Journal: Am J Cardiol Date: 2007-02-15 Impact factor: 2.778
Authors: Valentina Dargam; Hooi Hooi Ng; Sana Nasim; Daniel Chaparro; Camila Iansen Irion; Suhas Rathna Seshadri; Armando Barreto; Zachary C Danziger; Lina A Shehadeh; Joshua D Hutcheson Journal: Front Cardiovasc Med Date: 2022-05-25
Authors: Samantha J Borland; Julia Behnsen; Nick Ashton; Sheila E Francis; Keith Brennan; Michael J Sherratt; Philip J Withers; Ann E Canfield Journal: Int J Mol Sci Date: 2020-06-25 Impact factor: 5.923
Authors: Jason L Go; Komal Prem; Mohammed A Al-Hijji; Qing Qin; Christopher Noble; Melissa D Young; Lilach O Lerman; Amir Lerman Journal: Sci Rep Date: 2018-12-13 Impact factor: 4.379
Authors: Subramanian Dharmarajan; Mei Y Speer; Kate Pierce; Jake Lally; Elizabeth M Leaf; Mu-En Lin; Marta Scatena; Cecilia M Giachelli Journal: Front Cardiovasc Med Date: 2021-10-29